FOLH1 and prostate carcinoma: The PSMA-1 ligand is further modified for in situ synthesis of PSMA-targeted Au25 clusters (CY-PSMA-1-Au25), providing a high-affinity and highly effective radiosensitizer for prostate cancer (Luo et al., 2012).